CS
TAK icon

Candriam SCA’s Takeda Pharmaceutical TAK Stock Holding History

Candriam SCA’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-82
Closed -$1K – 827
2022
Q1 		$1K Buy
+82
New +$1.2K ﹤0.01% 805
2021
Q4 		– Sell
-76
Closed -$1K – 861
2021
Q3 		$1K Sell
76
-2
-3% -$34 ﹤0.01% 874
2021
Q2 		$1K Buy
+78
New +$1.33K ﹤0.01% 880

Other funds holding TAK

MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Candriam SCA's TAK Position: Q2 2022 in Review

Candriam SCA sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 82 shares — an estimated $1K sold.

Candriam SCA first reported a position in TAK in Q2 2021 and held it in 3 quarters. The position peaked at $1K in Q1 2022. 282 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

  • Candriam SCA reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Candriam SCA sold 82 Takeda Pharmaceutical shares in Q2 2022, an estimated $1K.
  • Candriam SCA first reported a position in Takeda Pharmaceutical in Q2 2021 and held it in 3 quarters.
  • Candriam SCA's Takeda Pharmaceutical position peaked at $1K in Q1 2022.
  • 282 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.